Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04675723

The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection

Clostridioides Difficile Infection Clinical Trial

Official title:
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection

Clinical Trial Summary

The study is being done to identify types of bacteria associated with the lining of the large intestine in people who have recently been treated for C. difficile infection to determine if there are features associated with recurrent disease.

Clinical Trial Description

Patients who have recently been diagnosed with C. difficile infection and completed treatment will be enrolled to undergo evaluation of the colonic mucosa via sigmoid biopsies. Participants will also complete surveys, blood draw and stool collection. Overall goals are to identify whether C. difficile is persisting in the colon mucosa after treated infection, and whether this, and other clinical and microbiome factors may be playing a role in disease recurrence. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04675723
Study type Observational
Source Mayo Clinic
Contact
Status Completed
Phase
Start date September 23, 2019
Completion date May 5, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Withdrawn NCT04679324 - The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
Recruiting NCT05693077 - Clostridioides Difficile Colonisation Phase 1
Completed NCT04668014 - The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
Completed NCT03183141 - ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection Phase 3
Recruiting NCT05709184 - Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection N/A
Terminated NCT05526807 - Ursodeoxycholic Acid in C. Difficile Infection N/A
Terminated NCT04802837 - Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects Phase 3
Active, not recruiting NCT04885946 - Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection N/A
Recruiting NCT04305769 - Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) Phase 2
Recruiting NCT06106698 - Washed Microbiota Transplantation for Clostridioides Difficile Infection
Active, not recruiting NCT04781387 - Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection Phase 2
Completed NCT03595566 - To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT03595553 - Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection Phase 3
Completed NCT04725123 - Addressing Personalized Needs in Clostridioides Difficile Infection N/A
Not yet recruiting NCT05852587 - Xylitol Use for Decolonization of C. Difficile in Patients With IBD Phase 1
Completed NCT03788434 - Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection Phase 2
Recruiting NCT05612672 - Evaluation of GeoHAI Implementation N/A
Recruiting NCT05320068 - Oral Vancomycin vs Placebo in the Prevention of Recurrence of Clostridioides Difficile's Infection Phase 3
Not yet recruiting NCT05330182 - LMN-201 for Prevention of C. Difficile Infection Recurrence Phase 2/Phase 3